BACKGROUND: Exsanguination associated with acute traumatic coagulopathy is a leading cause of death following injury. While platelets occupy a pivotal role in clot formation, clinical research has been scant because of complexities resulting from the need for rapid handling and complex testing of platelet functions. While the thrombin pathway has been proposed as a mediator of platelet dysfunction in trauma, it has not been systematically investigated. The purpose of this study was to evaluate the thrombin pathway in platelet dysfunction. METHODS: Forty trauma patients and 20 noninjured controls were enrolled in the study at a Level I trauma center. Platelet aggregation was tested by light transmission aggregometry with two agonists, adenosine diphosphate (ADP) and thrombin receptor agonist peptide (TRAP). Mean fluorescence intensity and percent positivity of CD62 on ADP-activated platelets were evaluated using flow cytometry. Enzyme-linked immunosorbent assays were performed to evaluate the concentrations of D-dimer, thrombin-antithrombin complex (TAT), and prothrombin fragment 1 + 2 (PF 1 + 2) in each sample. RESULTS: Compared with healthy controls, trauma patients had significantly decreased ADP- and TRAP-mediated platelet aggregation and ADP-mediated CD62 expression. In trauma patients, TRAP-mediated aggregation was inversely proportional to head Abbreviated Injury Scale (AIS) score. Glasgow Coma Scale (GCS) score was directly proportional to TRAP- and ADP-mediated aggregation. When compared with controls, significant differences of D-dimer, TAT, and PF 1 + 2 were found. Measures of shock, including admission blood pressure, pulse, base deficit, and lactate level, did not correlate with platelet dysfunction. CONCLUSION: Trauma patients have significantly lower levels of platelet activation and aggregation compared with healthy controls. Severity of head injury was significantly correlated with platelet dysfunction in a stepwise fashion. Trauma patients also have significantly increased levels of D-dimer, TAT, and PF 1 + 2 when compared with healthy controls. Our data suggest that the thrombin receptor pathway plays an important role in platelet dysfunction in trauma. LEVEL OF EVIDENCE: Prognostic and epidemiologic study, level III.
BACKGROUND: Exsanguination associated with acute traumatic coagulopathy is a leading cause of death following injury. While platelets occupy a pivotal role in clot formation, clinical research has been scant because of complexities resulting from the need for rapid handling and complex testing of platelet functions. While the thrombin pathway has been proposed as a mediator of platelet dysfunction in trauma, it has not been systematically investigated. The purpose of this study was to evaluate the thrombin pathway in platelet dysfunction. METHODS: Forty traumapatients and 20 noninjured controls were enrolled in the study at a Level I trauma center. Platelet aggregation was tested by light transmission aggregometry with two agonists, adenosine diphosphate (ADP) and thrombin receptor agonist peptide (TRAP). Mean fluorescence intensity and percent positivity of CD62 on ADP-activated platelets were evaluated using flow cytometry. Enzyme-linked immunosorbent assays were performed to evaluate the concentrations of D-dimer, thrombin-antithrombin complex (TAT), and prothrombin fragment 1 + 2 (PF 1 + 2) in each sample. RESULTS: Compared with healthy controls, traumapatients had significantly decreased ADP- and TRAP-mediated platelet aggregation and ADP-mediated CD62 expression. In traumapatients, TRAP-mediated aggregation was inversely proportional to head Abbreviated Injury Scale (AIS) score. Glasgow Coma Scale (GCS) score was directly proportional to TRAP- and ADP-mediated aggregation. When compared with controls, significant differences of D-dimer, TAT, and PF 1 + 2 were found. Measures of shock, including admission blood pressure, pulse, base deficit, and lactate level, did not correlate with platelet dysfunction. CONCLUSION:Traumapatients have significantly lower levels of platelet activation and aggregation compared with healthy controls. Severity of head injury was significantly correlated with platelet dysfunction in a stepwise fashion. Traumapatients also have significantly increased levels of D-dimer, TAT, and PF 1 + 2 when compared with healthy controls. Our data suggest that the thrombin receptor pathway plays an important role in platelet dysfunction in trauma. LEVEL OF EVIDENCE: Prognostic and epidemiologic study, level III.
Authors: Christopher C Verni; Antonio Davila; Steve Balian; Carrie A Sims; Scott L Diamond Journal: J Trauma Acute Care Surg Date: 2019-02 Impact factor: 3.313
Authors: Belinda H McCully; Christopher R Connelly; Kelly A Fair; John B Holcomb; Erin E Fox; Charles E Wade; Eileen M Bulger; Martin A Schreiber Journal: J Am Coll Surg Date: 2017-03-16 Impact factor: 6.113
Authors: M J George; J Burchfield; B MacFarlane; Y-W W Wang; J C Cardenas; N J White; B S Gill; C E Wade Journal: Transfus Med Date: 2017-09-15 Impact factor: 2.019
Authors: Benjamin R Huebner; Ernest E Moore; Hunter B Moore; Gregory R Stettler; Geoffrey R Nunns; Peter Lawson; Angela Sauaia; Marguerite Kelher; Anirban Banerjee; Christopher C Silliman Journal: Shock Date: 2018-12 Impact factor: 3.454
Authors: Alexander E St John; Jason C Newton; Erika J Martin; Bassem M Mohammed; Daniel Contaifer; Jessica L Saunders; Gretchen M Brophy; Bruce D Spiess; Kevin R Ward; Donald F Brophy; José A López; Nathan J White Journal: J Thromb Haemost Date: 2019-03-18 Impact factor: 5.824
Authors: Jessica C Cardenas; Xu Zhang; Erin E Fox; Bryan A Cotton; John R Hess; Martin A Schreiber; Charles E Wade; John B Holcomb Journal: Blood Adv Date: 2018-07-24
Authors: Alaina Garbens; Christopher J D Wallis; Georg Bjarnason; Girish S Kulkarni; Avery B Nathens; Robert K Nam; Raj Satkunasivam Journal: Can Urol Assoc J Date: 2017-11 Impact factor: 1.862